Integrin ligands and uses thereof
US-2020369613-A1 · Nov 26, 2020 · US
US12065458B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12065458-B2 |
| Application number | US-201916970130-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 15, 2019 |
| Priority date | Feb 17, 2018 |
| Publication date | Aug 20, 2024 |
| Grant date | Aug 20, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.
Opening claim text (preview).
The invention claimed is: 1. A compound of Formula III, or a pharmaceutically acceptable salt thereof, wherein, L 1 , L 2 , and L 3 are each linkers of the formula: L 4 is selected from the group consisting of: wherein indicates the point of attachment; R 4 is H or optionally substituted alkyl; X is O or S; and RNA comprises or consists of an RNAi agent. 2. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein X is O. 3. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein X is S. 4. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein L 1 , L 2 , and L 3 are each 5. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein L 1 , L 2 , and L 3 are each 6. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is selected from the group consisting of: Compound No. Structure 1-O-III 1-S-III 2-O-III 2-S-III 3-O-III 3-S-III 4-O-III 4-S-III 5-O-III 5-S-III 6-O-III 6-S-III 7-O-III 7-S-III 8-O-III 8-S-III 9-O-III 9-S-III 10-O-III 10-S-III 11-O-III
Conjugate · CPC title
interfering nucleic acids [NA] · CPC title
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title
containing three or more hetero rings · CPC title
having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.